Levosiz-M Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, formulated for the effective management of allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby alleviating symptoms such as sneezing, rhinorrhea, nasal congestion, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors (CysLT1), reducing inflammation and bronchoconstriction in conditions like asthma and allergic rhinitis. The synergistic action of these agents provides comprehensive relief from allergic manifestations by targeting multiple inflammatory pathways. Levosiz-M is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in mild to moderate asthma. It is generally well-tolerated, with a low incidence of adverse effects such as headache, fatigue, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment and those with a history of neuropsychiatric events. Levosiz-M should be administered as prescribed by a healthcare professional, with dosage adjustments based on clinical response and patient tolerability. This combination enhances patient compliance by reducing pill burden while effectively controlling allergic symptoms.

Dosage & How to Use